Therapeutically efficacious antibodies include anti-EGFR (Cetuximab) and anti-HER2 (Trastuzumab) used in various epithelial cancers and in HER-2-overexpressing breast cancer, respectively [4,7]. This evidence concerns the gene ERBB2 and breast carcinoma.